EPA:GNFT

Genfit - GNFT Stock Forecast, Price & News

€3.63

+0.01 (+0.28%)

(As of 03/28/2023 12:00 AM ET)

Add

Compare

Today's Range: €3.61
▼
€3.66
50-Day Range: €3.62
▼
€4.38
52-Week Range: N/A

Volume: 37,265 shs
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Genfit (EPA:GNFT) Stock

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

Receive GNFT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter.

GNFT Stock News Headlines

March 19, 2023 | americanbankingnews.com

Genfit (EPA:GNFT) Trading Up 0.9%

March 1, 2023 | finance.yahoo.com

GENFIT Announces Revenues and Cash Position as of December 31, 2022

March 29, 2023 | Investing Daily (Ad)

A 100% Win Rate In 2022…

The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you.

January 3, 2023 | msn.com

Financial, Pharma Gains Spur European Equities Higher in Tuesday Trading

January 1, 2023 | thestreet.com

Genfit's Fatty Liver Drug Study Results Are Coming. Here's What You Need to Know.

November 18, 2022 | technews.tmcnet.com

GENFIT Pipeline Day Highlights Diverse Product Portfolio in Underserved Liver Diseases

November 10, 2022 | finance.yahoo.com

GENFIT Reports Third Quarter 2022 Financial Information

October 27, 2022 | msn.com

European ADRs Move Higher in Wednesday Trading

March 29, 2023 | Investing Daily (Ad)

A 100% Win Rate In 2022…

October 12, 2022 | reuters.com

GNFT.O - Genfit SA (ADR) | Stock Price & Latest News | Reuters

June 14, 2022 | seekingalpha.com

GNFT Genfit S.A.

May 25, 2022 | finance.yahoo.com

GENFIT: May 25, 2022 Combined Shareholders Meeting results

May 11, 2022 | seekingalpha.com

Genfit reports Q1 results

May 11, 2022 | finance.yahoo.com

GENFIT Reports First Quarter 2022 Financial Information (Unaudited financial information under IFRS)

April 29, 2022 | finance.yahoo.com

GENFIT Announces Publication of the 2021 Universal Registration Document; the 2021 Annual Report on Form 20-F and Availability of Preparatory Documents for the Annual Combined Shareholders Meeting on May 25, 2022

April 14, 2022 | finance.yahoo.com

What Makes GENFIT S.A. Unsponsored ADR (GNFT) a New Buy Stock

April 11, 2022 | benzinga.com

SVB Leerink Maintains Outperform on Genfit, Lowers Price Target to $10

April 7, 2022 | seekingalpha.com

Genfit GAAP EPS of €1.23, revenue of €85.58M

April 7, 2022 | nz.finance.yahoo.com

GENFIT Reports Full-Year 2021 Financial Results and Provides Corporate Update

January 25, 2022 | nasdaq.com

GENFIT S.A. American Depositary Shares (GNFT)

January 11, 2022 | finance.yahoo.com

Can GENFIT S.A. Unsponsored ADR (GNFT) Climb 79% to Reach the Level Wall Street Analysts Expect?

December 17, 2021 | msn.com

Why Genfit Shares Are Rising

December 17, 2021 | markets.businessinsider.com

Pre-market Movers: GNFT, ABEO, SPRB, IO, CERN…

December 17, 2021 | msn.com

The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx

June 30, 2021 | finance.yahoo.com

GENFIT: June 30, 2021 Annual Shareholders Meeting results

June 25, 2021 | benzinga.com

GENFIT Highlights 2 Poster Presentations At 2 Scientific/Medical Events In Jun.

June 23, 2021 | finance.yahoo.com

GENFIT presents new NIS4® data in NASH at the International Liver Congress™ and the 81st Scientific Sessions of the American Diabetes Association

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive GNFT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: EPA
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: EPA:GNFT
CUSIP: N/A
CIK: N/A
Web: www.genfit.com
Phone: 33 3 20 16 40 00
Fax: N/A
Employees: 122
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Key Executives

Mr. Jean-Francois Mouney (Age 67)
Co-Founder & Chairman
Comp: $332.42k

Mr. M. Pascal Prigent (Age 54)
Chief Exec. Officer
Comp: $503.74k

Prof. Bart Staels (Age 59)
Co-Founder & Chairman of the Scientific Advisory Board

Mr. Thomas Baetz (Age 48)
Chief Financial Officer

Mr. Pascal Caisey (Age 54)
Chief Operating Officer

Dr. Dean W. Hum Ph.D. (Age 60)
Chief Scientific Officer

Mr. Laurent Lannoo (Age 52)
Corp. Sec. & Director of Legal Affairs

Ms. Stefanie Magner (Age 41)
Chief Compliance Officer & VP of International Legal Affairs

Ms. Emilie Desodt (Age 39)
Vice-Pres of HR

Mr. Jean-Christophe Marcoux (Age 45)
Chief Strategy Officer

Key Competitors

View All Competitors

GNFT Stock - Frequently Asked Questions

How have GNFT shares performed in 2023?: Genfit's stock was trading at €3.97 at the start of the year. Since then, GNFT stock has decreased by 8.7% and is now trading at €3.62.
View the best growth stocks for 2023 here.
What other stocks do shareholders of Genfit own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Genfit investors own include Alimentation Couche-Tard (ATD.B), Aecon Group (ARE), Algonquin Power & Utilities (AQN), Aptiv (APTV), American Tower (AMT), Advanced Micro Devices (AMD), Ambarella (AMBA), Albemarle (ALB), Adobe (ADBE) and Abbott Laboratories (ABT).

What is Genfit's stock symbol?: Genfit trades on the EPA under the ticker symbol "GNFT."
What is Genfit's stock price today?: One share of GNFT stock can currently be purchased for approximately €3.62.
How many employees does Genfit have?: The company employs 122 workers across the globe.
How can I contact Genfit?: Genfit's mailing address is Parc Eurasante 885 avenue Eugene Avinee, Loos, Hauts De France 59120. The official website for the company is www.genfit.com. The company can be reached via phone at 33 3 20 16 40 00.

This page (EPA:GNFT) was last updated on 3/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial